Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by gebremeskelon Nov 21, 2024 12:07pm
121 Views
Post# 36324013

Vantive/Baxter Split Can Get Complicated

Vantive/Baxter Split Can Get ComplicatedVantive will get three quarters of Baxter's Arkansas lab while Baxter will keep the northwest corner, containing plastics and blending operations. They're going to put up a wall to separate the two companies (no Mexican funding reported) Vantive will have 900 employees and Baxter will keep 200.

Mountain Home’s Baxter Lab to divide as part of $3.8B global deal

Baxter Healthcare’s Mountain Home facility will undergo a major operational split following Baxter International’s $3.8 billion sale of its Kidney Care segment to global investment firm Carlyle.
 
Plant Manager Robby Hill announced that the facility was in the process of splitting during Mayor Hillrey Adams’ November 14 roundtable meeting.
 
The split will create a new company called Vantive, which will take over approximately three-quarters of the Mountain Home plant while Baxter retains the northwest corner housing plastics and blending operations. The separation is scheduled for completion between late 2024 and early 2025, pending regulatory approvals.
 
Vantive will employ about 900 workers at the facility and will also take ownership of Baxter’s Midway facility. Baxter will maintain approximately 200 employees at its retained portion of the plant.
 
“We are in the process of actually separating the plant,” said Hill. “We’ll be putting fences, walls – you name it – to separate two companies under one roof.”
 
The transition will create 30-35 new positions across both companies. “These are not only hourly employees but also salary-exempt workers, so plant leadership,” Hill explained. “The main entrance that you see with the Baxter signs, that will be Vantive, and actually the Baxter side will be off of Russell Lane.”
 
The sale is part of Baxter International’s broader strategic realignment. Vantive will continue Baxter’s 70-year legacy in kidney care, offering products and services for peritoneal dialysis, hemodialysis, and organ support therapies. The company currently serves more than one million patients annually across more than 70 countries and generated $4.5 billion in revenue in 2023.
 
Chris Toth, currently executive vice president and group president of Kidney Care at Baxter, will serve as Vantive’s CEO, while Kieran Gallahue will serve as chairman. The company will operate under Carlyle’s ownership, a leading private equity firm that has invested over $40 billion in medical technology and diagnostic companies.
 
Hill remains optimistic about both companies’ futures in Mountain Home. “The good thing is we’re adding jobs,” he said. “The future’s bright for Vantive, the future’s bright for Baxter. We’re going to continue to grow here in Mountain Home.”
 
<< Previous
Bullboard Posts
Next >>